Phone: 040-23418836

040-40272617

Mobile: 98482 71555

LIMITED REVIEW REPORT

To, The Board of Directors, Saamya Biotech (India) Limited

We have reviewed the accompanying statement of Un-audited Financial Results of Saamya Biotech (India) Limited or the quarter ended 31st December, 2018 attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular NO. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date: 14th February, 2019.

For M M.Reddy& Co.
Chartered Accountants

M Mad usermans Feddy

Membersh P. 10 3077



🕽 Saamya Biotech (India) Ltd.

	SAAMYA BIO	TECH(INDIA) I	LIMITED				
	Statement of Un-Audited Re	sults for the Ou	arter ended 31	12.2018			
				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Ar	nount in La
S.No.	Particulars	Quarter Ended			Nine Months Ended		Year End
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.201
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I.	Revenue from Operations						
II.	Other Income						
III.	Total income (I+II)	-	-	-	•	-	
IV.	Expenses	-	-	-			
	(a) Cost of Materials consumed						
	(b) Purchase of stock-in-trade		-				
	(c) Changes in inventories of finished goods, work-in-progress and	 					
_	(d) Employee benefits expense	0.15	0.30	0.48	0.81	1.57	2
	(e) Finance Cost	- 0.15	0.50	0.40	- 0.01	- 1.57	
	(f) Depreciation and amortisation expense	-					
	(h)Other expenses	0.10	0.25	0.25	0.60	0.25	1
	Total Expenses	0.25	0.55	0.73	1.41	1.82	3
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	-0.25	-0.55	-0.73	-1.41	-1.82	
V 1.	Exeptional Items	-			-		
VII	Profit / (Loss) from before tax (V-VI)	(0.25)	(0.55)	(0.73)	(1.41)	(1.82)	(3.
VIII.	Tax expense		(-12-5)	(01.0)	(2312)	(2102)	(-
_	Current Tax	-	- 1	-	-	-	
	Deferred Tax	-	-	- 1	-		
IX.	Net Profit / (Loss) after Tax (VII-VIII)	(0.25)	(0.55)	(0.73)	(1.41)	(1.82)	(3.
	Other Comprehensive Inocme	-	-	- 1	-	- (===,	(5)
	Items that will not be reclasified to Profit or Loss	-	-	-	-	-	-
	Items that will be reclasified to Profit or Loss	-	-			_	
$\overline{}$	Total Comprehensive Income	(0.25)	(0.55)	(0.73)	(1.41)	(1.82)	(3.
	Paid-up equity share capital (Face Value of Rs. 10/- per share)	2,488.25	2,488.25	2,488.25	2,488.25	2,488.25	,
XIII	Earnings Per Equity Share of face value of Rs.10/- each)			2,.20.25	2,400,23	2,400.23	2,488.
	a) Basic & Diluted (In Rs.)	(0.00)	(0.00)	(0.00)	(0.01)	(0.01)	(0,

Date: 14.02.2019 Place: Hyderabad For SAAMYA BIOTECH (INDIO TIME

Dr. Y. Manivardhan R Managing Directo

NOTES:

1 The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting her

2 The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurent principles laid down in the Ind AS-34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting propouncements generally accepted in India.

The results are also available on the webiste of the Company www.saamyabiotech.com.

4 The Company is engaged in "Biotechnology" operating hence there are no separate reportable segments as per Ind AS -108 "Ope

Station: Hyderabad Date: 14.02.2019 For SAAMYA BIOTECH (INDIA) LIM

Dr. Y. Manivardhan Reddy Managing Director

Corporate Office: Plot No. 391- D. Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604. Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Webiste: www.saamyabiotech.com

Regd. Office: Suite 104-106, Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241 Fax: +91-40-2339 5214 e-mail: saamyaindia@saamyabiotech.com